DALLAS, May 21, 2014 /PRNewswire/ --
ReportsnReports.com offers "Vaccines: The End of Illness" and other vaccine market research reports focusing on vaccine technology, HIV, China's animal vaccine industry and cancer vaccine partnering terms and agreements.
Vaccines: The End of Illness 2014 market research report focuses on the most recent vaccine research, emphasizing their reputation as an unmatched tool of efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing a fundamental revolution, taking advantage of the profound understanding of the immune system and its ability to mount protective antibody production and cell-based responses to foreign antigens. Understanding these properties will not only enable the development of innovative diagnostics but also the advancement of therapeutic applications.
Specific Highlights of this report (http://www.reportsnreports.com/reports/286914-vaccines-the-end-of-illness.html ) include:
This report profiles some of the major pharma companies involved in vaccine R&D and a number of biotech companies developing new vaccine products and technologies - including 35 small pharma companies and 8 big pharma companies profiled
The logistics and management of the vaccine industry are increasingly based on partnerships between the private sector (pharma and biotech companies), government agencies (WHO) and large non-profits (such as the Gates Foundation).
An assessment of the future directions of vaccines as innovative medical therapies for a wide range of diseases.
Explores conditions not normally thought to be in purview of vaccination, including substance abuse and neurological disorders such as Alzheimer's disease and Parkinson's disease.
Survey of industry experts concerning the political economic and technological future of vaccine technology.
Companies discussed in Vaccines: The End of Illness research report include AstraZeneca (Medimmune), Baxter, GSK, J&J (Crucel), Merck, Novartis, Pfizer, Sanofi, AC Immune, Aeras, Alphavax, Astrellas, Bavarian Nordic, BiondVax Pharmaceuticals, Braasch Biotech LLC, Celldex, Chrontech, Emergent Biosolutions, EpiVax, GenVec, GeoVax, Genocea Biosciences, Immune Targeting Systems, Indian Immunologicals Limited, Inovio, Inviragen, Juvaris Biotherapeutics, Medicago, Mymetics, NovaRx, Novavax, Nuron, OPKO, Profectus Bioscience Inc, Sinovac, Sorrento Therapeutics, Inc., TapImmune, Valneva, VaxInnate, VaxLiant, VBI vaccines and Vical. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=286914 .
Vaccine Development Strategies - Refocusing Efforts to Address New Challenges is a 60 pages industry research report (http://www.reportsnreports.com/reports/280699-vaccine-development-strategies-refocusing-efforts-to-address-new-challenges.html ) published in February 2014. Scope of this report covers:
- This report providers readers with an understanding of the key developing trends in the vaccines market and how these are expected to impact on the overall competitive landscape, the major players and forecasted growth
- This report provides an overview of the preventative vaccines market, including insights into clinical development strategies, recommendations for maximizing potential for development of preventative vaccines and discussion about potential areas of growth in the near term
- The report provides in-depth analysis of the developing landscape for therapeutic vaccines, including recent activities of major pharmaceutical companies, insight into the challenges being faced by companies developing therapeutic vaccines and recommendations on clinical development strategies to overcome these potential obstacles and hurdles
- The report assesses the evolving competitive vaccines landscape, profiling the major pharmaceutical players and providing information into the emerging vaccines companies and assessing how the vaccines market is expected to develop in the short to medium term.
Request a sample of this report at http://www.reportsnreports.com/contacts/RequestSample.aspx?name=280699 .
The In-depth Research on China Animal Vaccine Industry, 2014 report says at present, there are 88 animal vaccine manufacturers in China, with 338 production lines. But most of enterprises are small in scale, vaccine production inspection is not standard and product structures are not reasonable. Market shares are occupied by a minority of enterprises. As per this report, the growth of China's animal vaccine market was slowing down in 2013, it was estimated that year-on-year growth was about 15% and the market scale reached CNY 10.22 billion in 2013, of which, swine vaccine accounted for 50% shares and poultry vaccine accounted for 36%. Complete report is available at http://www.reportsnreports.com/reports/276581-in-depth-research-on-china-animal-vaccine-industry-2014.html .
Cancer Vaccine Partnering Terms and Agreements 2014 market research report is of 231 pages and provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multi-component, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. This report contains over 200 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Complete report is available at http://www.reportsnreports.com/reports/149831-cancer-vaccine-partnering-agreements.html .
HIV Vaccine Market Opportunity & Clinical Pipeline Analysis is a 330 pages research report that says that in the next 5-8 years, it is expected that the pharmaceutical companies would focus more on the development of a successful efficient vaccine to control the spread of this disease. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. There needs to be complete scrutiny of every single technological area of HIV prevention R&D so as to reflect the best methods of channelizing the funds which are limited in nature. The funds need to be specifically directed towards only those products and approaches which have a high probability of succeeding, instead of those which are less promising. This report highlights:
- Introduction to HIV Vaccine & Mechanism
- Global HIV Incidence Scenario
- R&D Funding Scenario for HIV Vaccine
- FDA Regulatory Framework
- HIV Vaccine Clinical Trial by Phase & Country
- HIV Vaccines in Development Phase: More Than 100
- Most HIV Vaccines in Preclinical Phase: More Than 50
- Discontinued & Suspended HIV Vaccines Profiles
Complete report is available at http://www.reportsnreports.com/reports/276628-hiv-vaccine-market-opportunity-clinical-pipeline-analysis.html .
Explore more reports on the vaccines market at http://www.reportsnreports.com/tags/vaccine-market-research.html .
ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on: